Page last updated: 2024-10-20

uracil and Thrombopenia

uracil has been researched along with Thrombopenia in 10 studies

2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder

Research Excerpts

ExcerptRelevanceReference
"A double blind study to compare the efficacy of oral UFT (400 mg Tegafur (FT) plus 896 mg uracil/day) with that of oral FT (800 mg/day) on advanced breast cancer was performed between November, 1986, and November, 1989."9.07A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer. ( Nomura, Y; Ohsaki, A; Tashiro, H, 1994)
"In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin."7.78Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012)
"A double blind study to compare the efficacy of oral UFT (400 mg Tegafur (FT) plus 896 mg uracil/day) with that of oral FT (800 mg/day) on advanced breast cancer was performed between November, 1986, and November, 1989."5.07A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer. ( Nomura, Y; Ohsaki, A; Tashiro, H, 1994)
"In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin."3.78Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012)
") gemcitabine (GEM) at low dose plus oral chemotherapy with uracil-tegafur (UFT) and cyclophosphamide (CPA) in combination with radiotherapy (RT) against recurrent and advanced pancreatic cancers."2.71Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer. ( Endo, S; Hashimoto, K; Higami, T; Itakura, M; Koike, M; Maruyama, R; Nio, Y; Tsuji, M; Yamaguchi, K; Yano, S, 2005)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19902 (20.00)18.7374
1990's3 (30.00)18.2507
2000's3 (30.00)29.6817
2010's2 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Forns, X1
Poordad, F1
Pedrosa, M1
Berenguer, M1
Wedemeyer, H1
Ferenci, P1
Shiffman, ML1
Fried, MW1
Lovell, S1
Trinh, R1
Lopez-Talavera, JC1
Everson, G1
Wettergren, Y1
Carlsson, G1
Odin, E1
Gustavsson, B1
Chen, JS1
Yang, TS1
Lin, YC1
Jan, YY1
VIETTI, TJ1
BERRY, DH1
FERNBACH, DJ1
LUSHER, J1
SUTOW, WW1
Watanabe, O1
Shimizu, T1
Imamura, H1
Kinoshita, J1
Okabe, T1
Ogawa, K1
Haga, S1
Nio, Y1
Hashimoto, K1
Yano, S1
Itakura, M1
Koike, M1
Yamaguchi, K1
Endo, S1
Tsuji, M1
Higami, T1
Maruyama, R1
Tashiro, H1
Nomura, Y1
Ohsaki, A1
Ono, T1
Komatsu, M1
Hoshino, T1
Ishii, T1
Fujii, K1
Ohshima, S1
Mikami, K1
Masamune, O1
Fukuda, T1
Ichinose, Y1
Yano, T1
Kudoh, S1
Yoshimori, K1
Morikawa, T1
Kuba, M1
Niitani, H1
Palleschi, M1
Palleschi, A1
D'Amore, F1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOIS[NCT01704755]Phase 3381 participants (Actual)Interventional2012-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Participants in Each Arm With On-treatment Virologic Failure During the Treatment Period

Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log(subscript)10(subscript) IU/mL above the lowest value post baseline] at any time point during treatment), or fail to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01704755)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24

InterventionPercentage of participants (Number)
ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks0.5
ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks1.7

Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment

The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01704755)
Timeframe: 12 weeks after the last actual dose of study drug

InterventionPercentage of participants (Number)
ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks91.8
ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks96.5

Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment in the 24-week Arm Compared to the 12-week Arm

A sustained virologic response is defined as plasma Hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (< LLOQ) 12 weeks after the last dose of study drug. (NCT01704755)
Timeframe: 12 weeks after the last actual dose of study drug

InterventionPercentage of participants (Number)
ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks91.8
ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks96.5

Percentage of Participants With Virologic Relapse After Treatment

Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma Hepatitis C virus ribonucleic acid (HCV RNA) ≥ lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment. (NCT01704755)
Timeframe: within 12 weeks after the last dose of study drug

InterventionPercentage of participants (Number)
ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks5.9
ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks0.6

Reviews

1 review available for uracil and Thrombopenia

ArticleYear
[Drug induced cytopenias].
    La Clinica terapeutica, 1967, Dec-15, Volume: 43, Issue:5

    Topics: Agranulocytosis; Aminopyrine; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antihypertensive Agen

1967

Trials

6 trials available for uracil and Thrombopenia

ArticleYear
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:11

    Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dru

2015
A phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas.
    Japanese journal of clinical oncology, 2003, Volume: 33, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neo

2003
[Clinical usefulness of UFT and cyclophosphamide as salvage chemotherapy for patients with metastatic breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:5

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols;

2004
Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
    Oncology reports, 2005, Volume: 14, Issue:2

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap

2005
A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer.
    Japanese journal of clinical oncology, 1994, Volume: 24, Issue:4

    Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Meth

1994
UFT plus cisplatin in advanced non-small-cell lung cancer: interim analysis of 67 patients.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:9 Suppl 10

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cispla

1997

Other Studies

3 other studies available for uracil and Thrombopenia

ArticleYear
Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
    Cancer, 2012, Jun-01, Volume: 118, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2012
URACIL MUSTARY THERAPY IN METASTATIC WILMS'S TUMOR.
    American journal of diseases of children (1960), 1964, Volume: 108

    Topics: Anemia; Child; Drug Therapy; Leukopenia; Nausea; Neoplasm Metastasis; Nitrogen Mustard Compounds; Th

1964
[A case of advanced gastric cancer with multiple liver metastasis successfully treated with combination chemotherapy using UFT, CDDP and etoposide].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration

1996
chemdatabank.com